Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-11-13
2007-11-13
Kam, Chih-Min (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C530S300000, C424S009100, C435S069100, C536S023200
Reexamination Certificate
active
10091166
ABSTRACT:
The present invention relates to polynucleotide and polypeptide molecules for zamp1, a novel member of the β-defensin family. The polypeptides, and polynucleotides encoding them, exhibit anti-microbial activity and may be used in the study or treatment of microbial infections. The present invention also includes antibodies to the zamp1 polypeptides.
REFERENCES:
patent: 6809181 (2004-10-01), McCray et al.
patent: 95/32287 (1995-11-01), None
patent: 99/06554 (1999-02-01), None
patent: 00/07612 (2000-02-01), None
patent: 01/42467 (2000-06-01), None
patent: 00/46245 (2000-08-01), None
patent: 02/04487 (2002-01-01), None
patent: 02/40512 (2002-05-01), None
Jia et al., “Discovery of new human beta-defensins using a genomics-based approach,”Gene, 263(1-2):211-218 (Jan. 2001).
Lehrer et al. “Defensins: antimicrobial and cytotoxic peptides of mammalian cells,”Annu Rev Immunol., 11:105-128 (1993). Review.
Harder et al. “A peptide antibiotic from human skin,”Nature, 387(6636):861 (Jun. 26, 1997).
Incyte Pharmaceuticals, Inc. clone, 1996:INC1433022.
Incyte Pharmaceuticals, Inc. LIBRARY, 1996:BEPINON01.
Incyte Pharmaceuticals, Inc. LIBRARY, 1996: LPARNOT02.
Selsted et al., “Purification, primary structures, and antibacterial activities of beta-defensins, a new family of antimicrobial peptides from bovine neutrophils,”J Biol Chem., 268(9):6641-6648 (Mar. 25, 1993).
Bensch et al., “hBD-1: a novel beta-defensin from human plasma,”FEBS Lett., 368(2):331-335 (Jul. 17, 1995).
Bowie et al., “Deciphering the message in protein sequences: tolerance to amino acid substitutions,”Science, 247(4948):1306-1310 (Mar. 16, 1990).
Wells, J.A., “Additivity of mutational effects in proteins,”Biochemistry, 29(37):8509-8517 (Sep. 18, 1990).
Liu et al., “Structure and mapping of the human beta-defensin HBD-2 gene and its expression at sites of inflammation,”Gene, 222(2):237-244 (Nov. 19, 1998).
Porter et al., “Broad-spectrum antimicrobial activity of human intestinal defensin 5,”Infect Immun., 65(6):2396-2401 (Jun. 1997).
Daher et al., “Direct inactivation of viruses by human granulocyte defensins,”J Virol., 60(3):1068-1074 (Dec. 1986).
Martin et al., “Defensins and other endogenous peptide antibiotics of vertebrates,”J Leukoc Biol., 58(2):128-136 (Aug. 1995). Review.
Ouellette et al., “Paneth cell defensins: endogenous peptide components of intestinal host defense,”FASEB J., 10(11):1280-1289 (Sep. 1996). Review.
Lichtenstein et al., “In vitro tumor cell cytolysis mediated by peptide defensins of human and rabbit granulocytes,”Blood, 68(6):1407-1410 (Dec. 1986).
Zhu et al., “Isolation and structure of corticostatin peptides from rabbit fetal and adult lung,”Proc Natl Acad Sci U S A., 85(2):592-596 (Jan. 1988).
Territo et al., “Monocyte-chemotactic activity of defensins from human neutrophils,”J Clin Invest., 84(6):2017-2020 (Dec. 1989).
Tamura et al., “A marked decrease in defensin mRNA in the only case of congenital neutrophil-specific granule deficiency reported in Japan,”Int J Hermatol., 59(2):137-142 (Feb. 1994).
Higazi et al., “Defensin modulates tissue-type plasminogen activator and plasminogen binding to fibrin and endothelial cells,”J Biol Chem., 271(30):17650-5 (Jul. 26, 1996).
Yang et al., “Mammalian defensins in immunity: more than just microbicidal,”Trends Immunol., 23(6):291-6 (Jun. 2002).
Cicro et al., “Structural and functional characterization of hBD-1(Ser35), a peptide deduced from a DEFB1 polymorphism,”Biochem Biophys Res Commun., 293(1):586-92 (Apr. 26, 2002).
Schibli et al., “The solution structures of the human beta-defensins lead to a better understanding of the potent bactericidal activity of HBD3 againstStaphylococcus aureus,”J Biol Chem., 277(10):8279-89 (Mar. 8, 2002).
Harder et al., “Isolation and characterization of human beta -defensin-3, a novel human inducible peptide antibiotic,”J Biol Chem., 276(8):5707-13 (Feb. 23, 2001).
Goldman et al., “Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis,”Cell, 88(4):553-60 (Feb. 21, 1997).
Smith et al., “Cystic fibrosis airway epthelia fail to kill bacteria because of abnormal airway surface fluid,”Cell, 85(2):229-36 (Apr. 19, 1996).
Davies et al., “CFTR gene transfer reduces the binding ofPseudomonas aeruginosato cystic fibrosis respiratory epithelium,”Am J Respir Cell Mol Biol., 16(6):657-63 (Jun. 1997).
Dunsche et al., “The novel human beta-defensin-3 is widely expressed in oral tissues,”Eur. J. Oral. Sci., 109:121-124 (2002).
Cullor et al., “In vitro antimicrobial activity of defensins against ocular pathogens,”Arch Ophthalmol., 108(6):861-864 (Jun. 1990).
Schwab et al., “Corneal storage medium preservation with defensins,”Cornea, 11(5):370-375 (Sep. 1992).
Yeh et al., “Single-dose pharmacokinetics of indinavir and the effect of food,”Antimicrob Agents Chemother., 42(2):332-338 (Feb. 1998).
Haynes et al., “Innate defence of the eye by antimicrobial defensin peptides,”Lancet,352(9126):451-452 (Aug. 8, 1998).
Haynes et al., “Antimicrobial defensin peptides of the human ocular surface,”Br J Ophthalmol., 83(6):737-41 (Jun. 1999).
Sawicki et al., “Contraceptive potential of peptide antibiotics,”Lancet, 353(9151):464-5 (Feb. 6, 1999).
Garcia et al., “Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes ofXenopusoocytes and the induction of macrophage chemoattraction,”Cell Tissue Res., 306(2):257-64 (Nov. 2001).
Zasloff, M., “Antimicrobial peptides of multicellular organisms,”Nature, 415:389-395 (Jan. 2002).
Krisanaprakomkit et al., “Regulation of human beta-defensin-2 in gingival epithelial cells: the involvement of mitogen-activated protein kinase pathways, but not the NF-kappaB transcription factor family,”J Immunol., 168(1):316-324 (Jan 1, 2002).
Garcia et al., “Human beta-defensin 4: a novel inducible peptide with a specific salt-sensitive spectrum of antimicrobial activity,”FASEB J., express article 10.1096/fj.00-0865fje, published online on Jun. 18, 2001.
Duits et al., “Inhibition of hBD-3, but not hBD-1 and hBD-2, mRNA expression by corticosteroids,”Biochem Biophys Res Commun., 280(2):522-525 (Jan. 2001).
Hancock et al., “Antibiotic resistance inPseudomonas aeruginosa: mechanisms and impact on treatment,”Drug Resist Updat., 3(4):247-255 (Aug. 2000).
Biragyn et al., “DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induced systemic and mucosal immune responses,”Blood, 100(4):1153-1159 (Aug. 15, 2002).
Adler David A.
Baindur Nand
Beigel-Orme Stephanie
Holloway James L.
Sheppard Paul O.
Kam Chih-Min
Walsh Brian J.
ZymoGenetics Inc.
LandOfFree
Beta-defensins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Beta-defensins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Beta-defensins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3838013